Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma

I. Krajsová, P. Arenberger, R. Lakomý, E. Kubala, I. Březinová, A. Poprach, M. Šťastný, J. Mužík, B. Melichar,

. 2015 ; 35 (11) : 6303-10.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16009921

AIM: Evaluation of efficacy and safety of ipilimumab in patients with advanced, refractory melanoma enrolled into a national ipilimumab Expanded Access Program. PATIENTS AND METHODS: Adult patients with advanced/metastatic refractory melanoma were eligible for study inclusion. Ipilimumab was administered up to a total of four doses. RESULTS: One hundred and ninety-six patients were analyzed. Full ipilimumab induction was administered to 66.8% of patients. Median overall survival (OS) in the entire cohort was 7.5 months. Median OS for patients after four doses of ipilimumab was significantly longer than for patients with fewer doses (12.3 months vs. 2.0 months respectively; p<0.001). Median OS for patients with objective tumor response was 42.3 months. Normal baseline serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels, and the number of affected organs correlated with improved OS. CONCLUSION: The number of affected organs and combination of baseline LDH and CRP levels could potentially serve as predictors for both treatment response and OS.

000      
00000naa a2200000 a 4500
001      
bmc16009921
003      
CZ-PrNML
005      
20160412104730.0
007      
ta
008      
160408s2015 gr f 000 0|engg|
009      
AR
035    __
$a (PubMed)26504067
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Krajsová, Ivana $u Department of Dermato-oncology, University Hospital Prague, and Charles University First Medical Faculty, Prague, Czech Republic Ivana.Krajsova@vfn.cz.
245    10
$a Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma / $c I. Krajsová, P. Arenberger, R. Lakomý, E. Kubala, I. Březinová, A. Poprach, M. Šťastný, J. Mužík, B. Melichar,
520    9_
$a AIM: Evaluation of efficacy and safety of ipilimumab in patients with advanced, refractory melanoma enrolled into a national ipilimumab Expanded Access Program. PATIENTS AND METHODS: Adult patients with advanced/metastatic refractory melanoma were eligible for study inclusion. Ipilimumab was administered up to a total of four doses. RESULTS: One hundred and ninety-six patients were analyzed. Full ipilimumab induction was administered to 66.8% of patients. Median overall survival (OS) in the entire cohort was 7.5 months. Median OS for patients after four doses of ipilimumab was significantly longer than for patients with fewer doses (12.3 months vs. 2.0 months respectively; p<0.001). Median OS for patients with objective tumor response was 42.3 months. Normal baseline serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels, and the number of affected organs correlated with improved OS. CONCLUSION: The number of affected organs and combination of baseline LDH and CRP levels could potentially serve as predictors for both treatment response and OS.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a C-reaktivní protein $x metabolismus $7 D002097
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a L-laktátdehydrogenasa $x metabolismus $7 D007770
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x farmakoterapie $x mortalita $x patologie $7 D008545
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x mortalita $x patologie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a bezpečnost $7 D012449
650    12
$a záchranná terapie $7 D016879
650    _2
$a míra přežití $7 D015996
650    _2
$a časové faktory $7 D013997
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Arenberger, Petr $u Department of Dermatology, University Hospital Vinohrady Prague, and Charles University Third Medical Faculty, Prague, Czech Republic. $7 nlk19990072992
700    1_
$a Lakomý, Radek $u Department of Comprehensive Cancer Care, Masaryk Oncology Institute Brno, Brno, Czech Republic.
700    1_
$a Kubala, Eugen $u Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Březinová, Ivana $u Department of Oncology, Teaching Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Oncology Institute Brno, Brno, Czech Republic.
700    1_
$a Šťastný, Marek $u Bristol-Myers Squibb CZ, Prague, Czech Republic.
700    1_
$a Mužík, Jan $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and University Hospital Olomouc, Olomouc, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 35, č. 11 (2015), s. 6303-10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26504067 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160412104813 $b ABA008
999    __
$a ok $b bmc $g 1113350 $s 934289
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 35 $c 11 $d 6303-10 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace